At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
OCEA Ocean Biomedical
Post-Market Trading 05-16 17:26:42 EDT
1.70
-0.04
-2.30%
盘后1.72
+0.02+1.18%
16:54 EDT
High1.76Low1.58Vol279.74K
Open1.73D1 Closing1.74Amplitude10.34%
Mkt Cap58.90MTradable Cap6.32MTotal Shares34.65M
T/O477.82KT/O Rate7.53%Tradable Shares3.72M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential Capability to Protect Against Infection and Treat Severe Disease
GlobeNewswire  ·  05-16 20:01
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential Capability to Protect Against Infection and Treat Severe Disease
BRIEF-Ocean Biomedical Announces Receipt Of Notice From Nasdaq
Reuters  ·  04-25
BRIEF-Ocean Biomedical Announces Receipt Of Notice From Nasdaq
Ocean Biomedical Faces Compliance Challenges and Delays Report
TIPRANKS  ·  04-25
Ocean Biomedical Faces Compliance Challenges and Delays Report
Ocean Biomedical Inc reports results for the quarter ended in September - Earnings Summary
Reuters  ·  04-17
Ocean Biomedical Inc reports results for the quarter ended in September - Earnings Summary
MSTR, BIOR and ARBK among pre-market losers
seekingalpha  ·  04-01
MSTR, BIOR and ARBK among pre-market losers
Ocean Biomedical (NASDAQ: OCEA) Congratulates JV Partner, Virion Therapeutics, on Promising First-Ever Human Phase 1B Clinical Safety Data for Their Lead Checkpoint Modifier-Containing Immunotherapy for HBV Functional Cure, at Global APASL
GlobeNewswire  ·  03-28
Ocean Biomedical (NASDAQ: OCEA) Congratulates JV Partner, Virion Therapeutics, on Promising First-Ever Human Phase 1B Clinical Safety Data for Their Lead Checkpoint Modifier-Containing Immunotherapy for HBV Functional Cure, at Global APASL
GOEV, CHEK and MESO among pre-market losers
seekingalpha  ·  03-27
GOEV, CHEK and MESO among pre-market losers
Ocean Biomedical Inc expected to post a loss of 15 cents a share - Earnings Preview
Reuters  ·  03-26
Ocean Biomedical Inc expected to post a loss of 15 cents a share - Earnings Preview
Ocean Biomedical: Shooting Upward, But Not Somewhere I Want To Be (Rating Upgrade)
seekingalpha  ·  03-19
Ocean Biomedical: Shooting Upward, But Not Somewhere I Want To Be (Rating Upgrade)
Ocean Biomedical Inc expected to post a loss of 15 cents a share - Earnings Preview
Reuters  ·  03-19
Ocean Biomedical Inc expected to post a loss of 15 cents a share - Earnings Preview
Ocean Biomedical Inc expected to post a loss of 15 cents a share - Earnings Preview
Reuters  ·  03-13
Ocean Biomedical Inc expected to post a loss of 15 cents a share - Earnings Preview
Ocean Biomedical Inc expected to post a loss of 15 cents a share - Earnings Preview
Reuters  ·  03-09
Ocean Biomedical Inc expected to post a loss of 15 cents a share - Earnings Preview
Samsara, DocuSign, Gap among premarket gainers' pack
seekingalpha  ·  03-08
Samsara, DocuSign, Gap among premarket gainers' pack
BRIEF-Ocean Biomedical Inc - On March 1 Appointment Of Jolie Kahn, As Chief Financial Officer Of Ocean Biomedical Was Confirmed
Reuters  ·  03-05
BRIEF-Ocean Biomedical Inc - On March 1 Appointment Of Jolie Kahn, As Chief Financial Officer Of Ocean Biomedical Was Confirmed
JAGX, BBAI and BNTC among mid-day movers
seekingalpha  ·  03-05
JAGX, BBAI and BNTC among mid-day movers
ADIL, ANNX and MINM are among pre market gainers
seekingalpha  ·  03-01
ADIL, ANNX and MINM are among pre market gainers
Ocean Biomedical (NASDAQ: OCEA) Announces Joint Venture Partner, Virion Therapeutics to Present Their First Clinical Study Data as an Accepted Late Breaker Presentation at 2024 APASL Global Liver Meeting
GlobeNewswire  ·  02-29
Ocean Biomedical (NASDAQ: OCEA) Announces Joint Venture Partner, Virion Therapeutics to Present Their First Clinical Study Data as an Accepted Late Breaker Presentation at 2024 APASL Global Liver Meeting
ALT, HOLO and AEHL among mid-day movers
seekingalpha  ·  02-27
ALT, HOLO and AEHL among mid-day movers
Why MercadoLibre Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Benzinga  ·  02-24
Why MercadoLibre Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Ocean Biomedical Inc expected to post a loss of 15 cents a share - Earnings Preview
Reuters  ·  02-17
Ocean Biomedical Inc expected to post a loss of 15 cents a share - Earnings Preview

Introduction

Company Name.
Ocean Biomedical
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP. The company is based in Providence, Rhode Island. Ocean Biomedical, Inc. operates as a subsidiary of Poseidon Bio, LLC.
Issue price:
--